NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/24/2026 15:26
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15,646 mln
Float61.78 mln
Earnings Date08/06/2026
EPS
8.68
Strong
P / E
27.69
Elevated
Beneish M-Score
3.38
Highly suspicious
1-Year Forecast
291
Attractive
Relative Strength
91
/ 100
Top performer
Debt / Equity
1.84
High leverage
Business Description
Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.
